Investigating potential drug targets for the treatment of glioblastoma: a Mendelian randomization study
Abstract Glioblastoma (GBM), one of the most aggressive brain tumors, has a 5-year survival rate of less than 5%. Current standard therapies, including surgery, radiotherapy, and temozolomide (TMZ) chemotherapy, are limited by drug resistance and the blood–brain barrier. Integrating expression quant...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMC
2025-04-01
|
| Edice: | BMC Cancer |
| Témata: | |
| On-line přístup: | https://doi.org/10.1186/s12885-025-13979-3 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|